OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
December 03, 2021
Polymeric amorphous solid dispersions are the most commonly used technology, but amorphous APIs remain inherently unstable.
December 02, 2021
EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.
Particle analysis is a critical component of pharmaceutical development, providing assurances of the quality and performance of the final dosage form.
Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.
November 30, 2021
Researchers from MIT have developed novel nanosensors for the detection of the nucleocapsid and spike protein of the SARS-CoV-2 virus.
November 29, 2021
BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.
Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.
The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.
November 23, 2021
Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.
November 19, 2021
Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.